Filing summary
Entity and period: The supplied filing is Cyclacel Pharmaceuticals, Inc.’s unaudited Form 10-Q for the quarter and six months ended June 30, 2022—not a filing by Bio Green Med Solution, Inc. Figures below are in U.S. dollars; financial statement amounts are in millions unless stated otherwise.
Business context
Cyclacel is a clinical-stage biopharmaceutical company developing cancer medicines. Its principal programs are fadraciclib, a CDK2/9 inhibitor, and CYC140, a PLK1 inhibitor, both in Phase 1/2 studies. The company reported no revenue for the quarter or first half of 2022 and said it does not anticipate revenue for the foreseeable future.
Financial performance and liquidity
| Metric | Q2 2022 | Q2 2021 | Six months 2022 | Six months 2021 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Operating expenses | $5.785 | $6.100 | $12.344 | $10.405 |
| Operating loss | $(5.785) | $(6.100) | $(12.344) | $(10.405) |
| Net loss | $(4.575) | $(5.127) | $(8.683) | $(8.605) |
| Net loss per common share | $(0.46) | $(0.56) | $(0.87) | $(1.07) |
Because revenue was zero, a revenue-based operating margin is not meaningful. Q2 net loss narrowed year over year, while first-half net loss increased slightly. First-half results included $1.280 million of other income, primarily royalties under an asset purchase agreement with Thermo Fisher Scientific; the filing says the company cannot estimate the timing or amount of future receipts.
Research and development expense was $4.205 million in Q2 and $9.159 million for the first half, up 3% and 37%, respectively, year over year. First-half increases reflected clinical trial spending on fadraciclib and CYC140. General and administrative expense declined 21% in Q2 and 15% for the first half, partly because the prior-year period included a $0.4 million lease-assignment item and higher recruitment and professional costs.
At June 30, 2022, cash and cash equivalents were $29.077 million, down from $36.559 million at December 31, 2021. Working capital was $27.051 million; current liabilities were $5.026 million. Total liabilities were $5.139 million, including a $0.113 million lease liability. The filing reports no institutional credit financing or debt covenant obligations. Stockholders’ equity was $30.207 million, and accumulated deficit was $393.642 million.
For the first half, operating cash use was $8.690 million, investing cash use was $0.007 million, and financing provided $1.424 million. Financing included $1.525 million net proceeds from at-the-market share sales, partly offset by $0.101 million of preferred dividends. Cash declined by $7.482 million, including a negative $0.209 million foreign-exchange effect.
Changes, outlook, and risks
- Management estimated that June 30 cash would fund operating and capital needs into the second half of 2023. It said additional capital would be needed beyond that period and that available financing may not be obtainable on acceptable terms or at all. The company does not have enough funds to complete development and commercialization of any candidate.
- Management expects 2022 research and development expense to increase from 2021 as clinical programs advance, and general and administrative expense to decline slightly.
- Fadraciclib studies had treated 17 patients in a solid-tumor and lymphoma dose-escalation study and six patients in a hematologic-malignancy study. CYC140’s Phase 1/2 study began dosing in April 2022 and had treated three patients at the first dose level.
- The company cited potential clinical-trial delays and supply constraints from COVID-19, as well as uncertainty around future capital access. It said COVID-19 and geopolitical conditions could affect operations, clinical studies, and fundraising.
- Foreign-currency movements materially affected other comprehensive loss: first-half 2022 included a $22.046 million unrealized foreign-exchange loss on intercompany loans, partly offset by a $21.518 million translation gain. These items are distinct from net loss.
- Subsequent to quarter-end, the company sold 1,188,900 shares under its ATM agreement for approximately $1.6 million net proceeds. A quarterly preferred-stock cash dividend was paid August 1, 2022.
Important facts for investors to verify
- Confirm the issuer: this filing is for Cyclacel Pharmaceuticals, Inc.; the request metadata names a different company.
- Track cash burn, ATM usage, share dilution, and the timing and terms of any additional financing relative to the stated runway into the second half of 2023.
- Monitor trial enrollment, safety, dose selection, and clinical activity for fadraciclib and CYC140; the filing reports early-stage patient counts, not efficacy results.
- Assess how much future cash flow depends on UK research and development tax credits and variable Thermo Fisher royalty receipts.
- Review the company’s disclosed risk factors and currency exposure, including the large first-half foreign-exchange movements recorded outside net loss.